Vilaprisan

Summary

Vilaprisan (CHEMBL3989936) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including uterine corpus leiomyoma and leiomyoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 16
• Chemistry: 544.6 Da · C27H29F5O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989936
Name	Vilaprisan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	50915138
Molecular formula	C27H29F5O4S
Molecular weight	544.6
InChIKey	JUFWQQVHQFDUOD-ANRPBIDPSA-N

SMILES: C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C(C(F)(F)F)(F)F)O)C5=CC=C(C=C5)S(=O)(=O)C

IUPAC name: (8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-methylsulfonylphenyl)-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one

Also known as: BAY-1002670, BAY1002670, Vilaprisan, VILAPRISAN

Patent coverage: 33 distinct patent families (102 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
uterine corpus leiomyoma	3	MONDO:0007886	EFO:0000731
leiomyoma	3	MONDO:0001572	MONDO:0001572
endometriosis	2	MONDO:0005133	EFO:0001065

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE1	7
PHASE3	6
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03194646	PHASE3	TERMINATED	Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
NCT03240523	PHASE3	TERMINATED	A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
NCT03400943	PHASE3	TERMINATED	Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
NCT03400956	PHASE3	TERMINATED	Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
NCT03476928	PHASE3	TERMINATED	A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding
NCT03699176	PHASE3	WITHDRAWN	Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
NCT02131662	PHASE2	COMPLETED	Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap
NCT02465814	PHASE2	COMPLETED	Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids
NCT03573336	PHASE2	TERMINATED	Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis
NCT01816815	PHASE1	COMPLETED	Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670
NCT02262663	PHASE1	COMPLETED	Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan
NCT02456129	PHASE1	COMPLETED	Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan
NCT03092999	PHASE1	COMPLETED	Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)
NCT03210246	PHASE1	COMPLETED	Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)
NCT03342859	PHASE1	TERMINATED	Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
NCT03411980	PHASE1	COMPLETED	Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).